Literature DB >> 628

Investigation into some imidazoline compounds, with respect to peripheral alpha-adrenoceptor stimulation and depression of cardiovascular centers.

W Kobinger, L Pichler.   

Abstract

Peripheral alpha-adrenoceptor stimulation was tested by means of hypertensive effects of the drugs following i.v. injection in spinal rats. Naphazoline (NP), oxymetazoline (OM), St 91-2-(2,6-diethylphenylimino)-2-imidazolidine--and St 1697--2-(2-ethyl, 6-methylphenylimino)-2-imidazolidine--were 3 to 5 times more potent in tthis respect thatn clonidine (CLON) whereas St 363--2-(2,4-dichlorophenylimino)-2-imidazolidine--and xylazine (XY) exerted only approx. 1/20 the effect of that of clonidine. Sympathoinhibitory activity after i.v. injection was tested by the bradycardiac effect in vagotomized rats; St 1697, St 363 and XY were active, approx. 1/10-1/30 of CLON, whereas NP, OM and St 91 were inactive. However, following intracisternal (i.ci.) injection of cardiovascular depression, typical for clonidine: (1) in dogs with blocked beta-adrenoceptors, the drugs facilitated the vagally meditated cardiodepressor reflex in response to baroreceptor stimulation by i.v. injection of angiotensin; (2) in dogs treated with atropine and in (3) vagotomized cats (only NP, OM and St 363) a long lasting decrease in heart rate was observed. Some of the experiments were complicated by increases in blood pressure, due to the "leakage" of small amounts of the highly vasopressor active drugs, from the cisternal spaces into the peripheral circulation. The majority of results indicated, that the central cardiovascular depressor effects of the tested drugs depend on their alpha-adrenoreceptor stimulating potency and on their ability to penetrate from cerebrospinal fluid or from the blood to cardiovascular centers. Relationships between the ability for penetration and the lipoid affinity are discussed.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 628     DOI: 10.1007/BF00500048

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  15 in total

1.  Localization in the CNA of adrenoceptors which facilitate a cardioinhibitory reflex.

Authors:  W Kobinger; L Pichler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1975       Impact factor: 3.000

2.  Involvement of adrenergic receptors in central vagus activity.

Authors:  W Kobinger; A Walland
Journal:  Eur J Pharmacol       Date:  1971-09       Impact factor: 4.432

3.  [On the mechanism of action of a new antihypertensive substance with imidazoline structure].

Authors:  W Kobinger
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1967

4.  Comparison of haemodynamic effects of alpha-sympathomimetic drugs.

Authors:  A M Autret; H Schmitt; S Fenard; N Pétillot
Journal:  Eur J Pharmacol       Date:  1971-01       Impact factor: 4.432

5.  [Blood circulation studies with 2-(2,6-dichlorphenylamino)-2-imidazoline hydrochloride].

Authors:  W Kobinger; A Walland
Journal:  Arzneimittelforschung       Date:  1967-03

6.  Comparative pharmacodynamics of sympathomimetic imidazolines; studies on intestinal smooth muscle of the rabbit and the cardiovascular system of the cat.

Authors:  M Mujić; J M van Rossum
Journal:  Arch Int Pharmacodyn Ther       Date:  1965-06

7.  [Effect of sympathomimetics on the vasomotor centers].

Authors:  H Schmitt; S Fénard
Journal:  Arch Int Pharmacodyn Ther       Date:  1971-04

8.  Central and peripheral alpha adrenergic activity of imidazoline derivatives.

Authors:  H S Boudier; G Smeets; G Brouwer; J van Rossum
Journal:  Life Sci       Date:  1974-09-01       Impact factor: 5.037

9.  Relationship between activity and structure in derivatives of clonidine.

Authors:  W Hoefke; W Kobinger; A Walland
Journal:  Arzneimittelforschung       Date:  1975-05

10.  Evidence for increased vagal tone and enhancement of baroreceptor reflex activity after xylazine (2-(2,6-dimethylphenylamino)-4-H-5,6-dihydro-1,3-thiazine) in anesthestized dogs.

Authors:  M J Antonaccio; R D Robson; L Kerwin
Journal:  Eur J Pharmacol       Date:  1973-09       Impact factor: 4.432

View more
  8 in total

1.  Pharmacological characterization of B-HT 933 (2-amino-6-ethyl-4,5,7,8,-tetrahydro-6H-oxazolo-[5,4-d]-azepindihydrochloride) as a hypotensive agent of the "clonidine-type".

Authors:  W Kobinger; L Pichler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-10       Impact factor: 3.000

Review 2.  Rudolf Buchheim lecture. Drugs as tools in research on adrenoceptors.

Authors:  W Kobinger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-02       Impact factor: 3.000

3.  Differential effects of substance P on serotonin-modulated spinal nociceptive reflexes.

Authors:  R M Murphy; F P Zemlan
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

4.  Effects of alpha 2-adrenoceptor agonists and of related compounds on aggregation of, and on adenylate cyclase activity in, human platelets.

Authors:  K A Clare; M C Scrutton; N T Thompson
Journal:  Br J Pharmacol       Date:  1984-06       Impact factor: 8.739

5.  Reversal of reserpine-induced ptosis in the mouse by alpha-adrenoceptor-agonists.

Authors:  M J Deniard; J Meignen; F V DeFeudis
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

6.  Relation between central sympathoinhibitory and peripheral pre- and postsynaptic alpha-adrenoceptors as evaluated by different clonidine-like substances in rats.

Authors:  W Kobinger; L Pichler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980       Impact factor: 3.000

7.  Participation of cardiac presynaptic alpha 2-adrenoceptors in the bradycardiac effects of clonidine and analogues.

Authors:  A de Jonge; P B Timmermans; P A van Zwieten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-08       Impact factor: 3.000

Review 8.  Suitability of urethane anesthesia for physiopharmacological investigations in various systems. Part 2: Cardiovascular system.

Authors:  C A Maggi; A Meli
Journal:  Experientia       Date:  1986-03-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.